

UCLA

UCLA Previously Published Works

Title

Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions

Permalink

<https://escholarship.org/uc/item/713180w7>

Journal

Addiction, 102(Suppl. 1)

ISSN

0965-2140

Authors

Shoptaw, S
Reback, C J

Publication Date

2007-04-01

DOI

10.1111/j.1360-0443.2006.01775.x

Peer reviewed

Methamphetamine Use and Infectious Disease Related Behaviors
in Men Who Have Sex With Men: Implications for Interventions

Short Title: Interventions with Methamphetamine Users

Word Count: 3983

Steven Shoptaw, PhD

Cathy J. Reback, PhD

UCLA Department of Family Medicine and
Integrated Substance Abuse Programs
David Geffen School of Medicine
10880 Wilshire Blvd, Suite 1800
Los Angeles, CA 90095-7087

Van Ness Recovery House, Prevention Division
Friends Research Institute, Inc.
UCLA Integrated Substance Abuse Programs
1419 N. La Brea Blvd
Los Angeles, CA 90028

Address all correspondence regarding this article to:

Steven Shoptaw, PhD
Department of Family Medicine
David Geffen School of Medicine
10880 Wilshire Blvd, Suite 1800
Los Angeles, CA 90095-7087
Office: 310 794 6206
Fax: 310 794 2808
Email: sshoptaw@mednet.ucla.edu

Disclaimers: None

ABSTRACT

Aims: Review the current evidence regarding the prevalence of methamphetamine use among men who have sex with men (MSM) and to evaluate the factors that contribute to methamphetamine use and potential for sexual transmission of HIV and other infectious diseases.

Methods: Databased reports address: (1) epidemiology of methamphetamine use in MSM; (2) methamphetamine use and risk behaviors for sexually transmitted infections; and (3) interventions.

Findings: Methamphetamine use is highly prevalent in MSM. Strong associations between methamphetamine use and HIV-related sexual transmission behaviors are noted across studies of MSM and correspond to increased incidence for HIV and syphilis compared to MSM who do not use the drug. Behavioral treatments produce sustained reductions in methamphetamine use and concomitant sexual risk behaviors among methamphetamine-dependent MSM.

Conclusions: Brief screening of methamphetamine use for MSM who seek physical, mental health and substance abuse services is recommended. Behavioral interventions address methamphetamine use may range from brief interventions to intensive outpatient treatments.

INTRODUCTION

The prevalence of lifetime substance use among men who have sex with men (MSM) is substantially higher than that for heterosexual men or women^{1,2}. [“MSM” is used as a narrow term that describes sexual behavior while “gay or bisexual” reflects the adoption of a sexual identity and a culture shared by MSM that extends beyond sexual behaviors.] Methamphetamine use is prevalent among MSM living in the United States^{1,3}, Australia and Western Europe⁴. There are expressions of concern that this drug in particular may lead to accelerating new HIV infections⁵ and to potential for promoting transmission of multi-drug resistant HIV^{5,6}. Among MSM, methamphetamine is frequently used alone⁷ and in combination with other club drugs^{8,9} (i.e., methamphetamine, amphetamine, ecstasy, cocaine, GHB, and ketamine). With its rise in popularity in communities of gay and bisexual men, evidence has accumulated to detail not only its epidemiology, but also to describe cultural factors that facilitate its use and to indicate important ways in which methamphetamine is combined with sexual transmission behaviors. Evidence also is accumulating on interventions that should be considered when articulating a comprehensive approach to address the high rates of methamphetamine use in MSM. This manuscript reviews the recent evidence on the epidemiology, linkages between methamphetamine use and HIV-related sexual transmission behaviors, and evidence-based interventions with methamphetamine-using MSM.

Epidemiology of Methamphetamine Use: Around the world, 35 million people use amphetamine type stimulants (includes methamphetamine and ecstasy - MDMA), which eclipses use of all other illicit drugs excepting cannabis¹⁰. Reports using probability sampling in the U.S. indicate that up to 13% of adult MSM used methamphetamine in the previous 6 months². Among MSM aged 15-22, 20.1% admitted using methamphetamine¹¹ over a similar period.

Important questions arise regarding factors that may explain the high prevalence of methamphetamine use in MSM. One of the first qualitative studies on methamphetamine use in MSM described three shared identities relative to the drug: gay identity (the importance of methamphetamine use to facilitate gay sexual experiences and to access gay culture), crystal user identity (the perception of one's own use of methamphetamine in comparison to that of other gay or bisexual methamphetamine users) and identity regarding HIV (the ways in which methamphetamine assuages thoughts about HIV-related issues for both infected and uninfected men).¹² Qualitative reports are consistent in describing ways in which crystal methamphetamine is reported to facilitate uninhibited sexual behaviors, while ecstasy (MDMA) is reported to enhance feelings of euphoria and group connectedness¹³. Stimulant-using Latino gay men also report using methamphetamine for sexual reasons while cocaine enhances social connections¹⁴. In contrast, heterosexual males and females seeking treatment of methamphetamine abuse who indicate methamphetamine is used to get high, to have fun, to get energy, to use with friends, to stay awake, to "escape," to enhance sex, to lose weight and to work more.¹⁵ As well as informing the process of tailoring interventions that aim to reduce methamphetamine use in MSM, cultural factors unique to gay and bisexual methamphetamine users highlight how feelings of stigma and negative personal attributions, internalized or otherwise, are experienced by this group of drug users¹⁶.

Methamphetamine Use and Risk Behaviors for Sexually Transmitted Infections in MSM: Physiological and psychological properties of methamphetamine make it efficient for facilitating behaviors that transmit HIV and other infectious diseases. The drug is inexpensive (approximately \$25-40 U.S. per gram) and has a long half-life (8-12 hours) that enables long sexual episodes. The drug induces euphoria, brightens mood, eliminates fatigue, decreases

appetite (leading to weight loss), focuses attention and for many, heightens libido¹⁷. MSM who use methamphetamine engage in high rates of HIV-related sexual risk behaviors.¹⁸ In young MSM, substances are frequently combined with sex: 42.8% reported being under the influence of alcohol when having sex, 28.2% used marijuana, 9.2% used amphetamines, 8.7% used cocaine and 8.0% used amyl nitrite during sex in the previous 6 months³.

MSM who use methamphetamine and who are HIV-infected also are likely to engage in sexual risk behaviors when under the influence, although not always with HIV-negative partners¹⁹. Among HIV-positive injectors, use of methamphetamine corresponds with significant healthcare disparities as marked by lower employment, lower annual income, less identification with the gay community, more likely to be diagnosed with AIDS and more likely to be sexually abused than non-injection drug users or non-drug using MSM²⁰. HIV-positive MSM who inject are also more likely to report experiences with stigma over being a methamphetamine user and educational status than non-injecting methamphetamine users²¹.

While methamphetamine use appears associated with high-risk sexual behaviors in MSM, it is difficult to specify direct effects of the drug on HIV transmission. Methamphetamine dries the mucosa and reduces the sensitivity of the rectal and genital areas. This can facilitate longer and rougher sexual episodes and contribute to increased likelihood of bruising and tearing in the region and of increasing opportunities for transmission of infectious disease. Use of amyl nitrites and other drugs that can facilitate sexual functioning can also increase risks for disease transmission^{22,23}. Chronic use of methamphetamine can cause some men to experience erectile dysfunction, although sildenafil, vardenafil or tadalafil are used to counter this effect. The combination of sildenafil (and perhaps related compounds of vardenafil and tadalafil) with amyl

nitrite in the presence of recreational use of methamphetamine and other club drugs has been reported to cause death²⁴.

HIV/AIDS surveillance in the United States shows MSM to be the only behavioral risk group with increasing incidence.²⁵ Estimates of HIV incidence in MSM averages 1.55 per 100 persons per year (95% CI = 1.23-1.95)²³, which corresponds to a prevalence of 19.1% in California (95% CI=12.8% to 25.3%)²⁶. Incidence rates are doubled²³ or tripled²⁷ for MSM who use amphetamines compared to non drug-using MSM. These findings, though localized to the epidemic in the United States, indicate that methamphetamine has profound effects on decision-making about sexual behaviors that increase risks for disease transmission in this already at-risk group.

Methamphetamine use is also associated with transmission of other infectious diseases in MSM. In one recent report of 1,318 gay and bisexual men at a public health department clinic, 4.0% tested positive for early syphilis²⁸. Factors that associated significantly with syphilis infection included being of nonwhite race, being HIV infected, using methamphetamine with sildenafil, using methamphetamine alone, using sildenafil without methamphetamine, stronger gay community affiliation, and having recent Internet sex partners. The increased likelihood of HIV-infection in MSM with early syphilis suggests sero-sorting when some HIV-infected men select sexual partners. Among these, use of methamphetamine and sildenafil increased their odds for becoming infected with syphilis. The robust nature of the linkages between methamphetamine use and risk behaviors that transmit infectious disease in MSM have led some to promote methamphetamine use reduction as part of comprehensive HIV prevention plans.

Behavioral Interventions: One strategy to interventions involves providing prevention services to reduce sexual risk behaviors among methamphetamine using MSM. Outcomes from

this approach demonstrate that enhanced behavioral HIV prevention using multiple group sessions significantly reduces rates of serodiscordant unprotected anal intercourse over standard HIV prevention in the shorter term²⁹, with no differences between groups observed to long-term evaluations. Yet, participants in this trial who used methamphetamine were statistically more likely to engage in HIV-related risk behaviors and to seroconvert than non-drug users³⁰, indicating that prevention interventions designed to reduce sexual risk behaviors may have initial effects for MSM in general, with limited impact in methamphetamine using MSM.

Biomedical Prevention: Given the high rates of methamphetamine use among MSM and corresponding HIV-related risk behaviors, biomedical prevention approaches may be especially appropriate in helping HIV-negative men remain uninfected. Two methods of biomedical prevention are considered, including non-occupational post exposure prophylaxis (nPEP) and more recently, pre-exposure prophylaxis (PrEP). N-PEP entails initiation of a short course of antiretroviral therapy following potential exposure to HIV from sexual or drug-related behaviors. Guidelines advise initiation of a 2- or 3-drug antiretroviral therapy immediately after an exposure event (within 36-72 hours) to reduce the probability of HIV seroconversion³¹. In a Brazilian report, 200 MSM received 4 days of antiretroviral medications to take home with instructions to begin the medication immediately following a potential exposure event followed by 24 days of additional medication. Over approximately 24 months, nPEP was started by 68 MSM following 109 risk events. A total of 11 seroconversions were reported; 10 among MSM who did not use nPEP and one among those who did, a non-statistically significant difference³². Reasons for not using nPEP included having sex with a steady partner and not considering the risk event sufficiently high risk to start nPEP, a key problem with nPEP³³. In high-risk groups of MSM such as methamphetamine users, clinical benefits to biomedical HIV prevention using nPEP may

be of sufficient level to balance side effects and costs from the approach. Moreover, nPEP provides an optimal point for screening for sexually transmitted infections additional to HIV for MSM who seek nPEP.³⁴

Pre-exposure prophylaxis contrasts with nPEP by providing antiretroviral therapy to high-risk individuals *prior* to a potential exposure event in order to help the immune system resist HIV infection. Although clinical trials will likely not demonstrate definitive efficacy of this approach, pre-exposure prophylaxis may represent a viable and potentially safe method for biomedical HIV prevention in the absence of an effective vaccine -- particularly in groups with high incidence rates. This approach to biomedical prevention, however, requires substantial effort to document safety and efficacy prior to issuing guidelines recommending its use, even in high-risk groups.

Behavioral Treatments. Behavioral interventions that address methamphetamine use and thereby reduce concomitant HIV-related sexual transmission behaviors in MSM represent an alternate approach. One low-intensity intervention, the 5 A's, can be implemented in most clinical settings adapts the practice guideline for smoking cessation for use with methamphetamine-using MSM³⁵. In communities with high prevalence of methamphetamine use in MSM, a first step is to screen for methamphetamine use (Ask) at points of physical, mental health, and substance abuse care using a structured progress note that assesses methamphetamine use. For those who admit to methamphetamine use, the clinician advises in a clear manner that the individual quit their use of this drug (Advise). Next the clinician inquires whether the client is willing to make a quit attempt (Assess) and assists him by evaluating the client's level of methamphetamine use, by linking the client to available community and professional resources, and by recommending medical evaluation for the client, particularly if the individual is HIV

infected (Assist). Clinicians arrange for future evaluation, either by scheduling repeat visits or telephone calls to follow-up (Arrange).

Brief, low intensity interventions may help some MSM who use methamphetamine at recreational levels to reduce or eliminate methamphetamine their drug use. A substantial group, however, may require intensive interventions that integrate behavioral drug abuse treatment with HIV sexual risk reductions. Currently, no medications are approved for treating methamphetamine dependence. Yet behavioral therapies have shown efficacy in assisting individuals with methamphetamine abuse or dependence in discontinuing their drug use.

More intensive behavioral therapies are conducted out of drug abuse treatment clinics and involve at least weekly visits. In the largest randomized trial, cognitive behavioral therapy (Matrix Model) was compared with treatment as usual (TAU) in eight sites and 978 participants³⁶. Participants assigned to Matrix Model, which uses group sessions to teach skills for instilling abstinence from methamphetamine, for avoiding relapse and for resuming abstinence should relapse occur, were 38% more likely to stay in treatment and were 31% more likely to provide a methamphetamine-metabolite free urine sample during treatment than participants receiving TAU. Treatment greatly reduced drug use in both conditions from an average of 11 of the previous 30 days at baseline to slightly over 4 days at 6-month follow-up visits.

Evidence has also accumulated for the use of contingency management (CM; i.e., providing vouchers of increasing value for successive urine samples documenting stimulant abstinence) for treatment of methamphetamine dependence. In a trial of 171 predominantly heterosexual stimulant dependent individuals randomly assigned to a CBT condition (Matrix Model), a CM condition, or a CBT+CM condition, results comparing the metabolite-free urine

samples produced per condition over a 12-week study period featuring thrice weekly urine collection showed the CM condition (mean=27.6) and the CBT+CM condition (mean=28.6) to significantly outperform the CBT condition (mean=15.5). Reductions in self-reported drug use, however, were similar for all three conditions, with those at baseline averaging between 9 to 10 days of use for the previous 30 days and those at one-year follow-up visits averaging between 2 to 5 days of use.

These efficacious drug abuse treatments for heterosexual methamphetamine abusers appear to work similarly with MSM. In one controlled trial,³⁷ methamphetamine-dependent gay and bisexual men were randomly assigned to one of the following behavioral drug abuse treatment conditions for 16 weeks: (1) a CBT condition (the Matrix Model; n=40), which served as a standard condition; (2) CM (n=42); (3) combined CBT+CM (n=40); and (4) an adapted gay-specific cognitive behavioral therapy (GCBT; n=40) that translated the core elements of standard CBT to reflect referents of gay culture. Results showed CM containing conditions to yield significantly longer periods of consecutive urine verified methamphetamine abstinence compared to CBT during the treatment period (CBT=2.1 weeks; CM=5.1 weeks; CBT+CM=7.0 weeks; GCBT= 3.5 weeks). As in the Rawson trial, however, ratings of self-reported methamphetamine use reduced similarly across conditions from 9 to 10 of the previous 30 days at baseline to 3 to 5 of the previous 30 days at one-year follow-up visits. Along with drug use reductions, episodes of unprotected anal intercourse with other than primary partner in the past 30 days were reduced from an average of 3 episodes in the past 30 days at baseline to an average of less than 1 episode at one-year follow-up visits. That both drug use and sexual risk behaviors were reduced substantially to distal evaluations provides strong suggestions for methods to reduce intertwining risk behaviors.

Conclusion: Methamphetamine use is prevalent among MSM in the U.S., Australia and Britain. Use of methamphetamine may range from recreational to chronic to addiction, however, the data consistently indicate that MSM who use this drug engage in concomitant HIV-related sexual transmission behaviors. Several public health indicators suggest higher rates of infection with HIV and syphilis for methamphetamine using MSM compared to MSM who do not use the drug. In communities of MSM with high prevalence of methamphetamine use and concomitant HIV-related sexual risk behaviors, a continuum of interventions should be available to meet the methamphetamine-using MSM “where he is at” and to assess his readiness to change. When MSM seek intervention in settings that provide primary care, HIV care or mental health services, one reasonable approach is for the care provider to engage the individual around his level of methamphetamine use (screen) and his desire for drug abuse treatment. Based on the response, a range of options can be engaged that include HIV prevention to brief intervention to one of a variety of efficacious behavioral drug abuse treatments. Such a coordinated and comprehensive approach to intervention in this high-risk group seems appropriate as we enter the third decade of the AIDS epidemic and the second decade of the epidemic of methamphetamine use in communities of MSM.

ACKNOWLEDGEMENT: This report was supported in part by NIDA grant R01 DA 11031 and the NIMH 058107.

REFERENCES

1. Cochran SD, Ackerman D, Mays VM, Ross MW. Prevalence of non-medical drug use and dependence among homosexually active men and women in the US population. *Addiction*. 2004; 99:989-98.
2. Stall R, Paul JP, Greenwood G, Pollack LM, Bein E, Crosby GM, Mills TC, Binson D, Coates TJ, Catania JA. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men's Health Study. *Addiction*. 2001; 96:1589-601.
3. Celentano DD, Valleroy LA, Sifakis F, MacKellar DA, Hylton J, Thiede H, McFarland W, Shehan DA, Stoyanoff SR, LaLota M, Koblin BA, Katz MH, Torian LV; for the Young Men's Survey Study Group. Associations between substance use and sexual risk among very young men who have sex with men. *Sex Transm Dis*. 2006; 33:265-71.
4. Bolding G, Hart G, Sherr L, Elford J. Use of crystal methamphetamine among gay men in London. *Addiction*. 2006; 101:1622-1630.
5. Urbina A, Jones K. Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. *Clin Infect Dis*. 2004; 38:890-4.
6. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, Kim A, Chung C, Jean-Pierre P, Horowitz A, La Mar M, Wrin T, Parkin N, Poles M, Petropoulos C, Mullen M, Boden D, Ho DD. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. *Lancet*. 2005; 365:1031-8.
7. Halkitis PN, Fischgrund BN, Parsons JT. Explanations for methamphetamine use among gay and bisexual men in New York City. *Subst Use Misuse*. 2005; 40:1331-45.

8. Mansergh G, Purcell DW, Stall R, McFarlane M, Semaan S, Valentine J, Valdiserri R. CDC consultation on methamphetamine use and sexual risk behavior for HIV/STD infection: summary and suggestions. *Public Health Rep.* 2006; *121*:127-32.
9. Mattison AM, Ross MW, Wolfson T, Franklin D. San Diego HIV Neurobehavioral Research Center Group. Circuit party attendance, club drug use, and unsafe sex in gay men. *J Subst Abuse.* 2001. *13*:119-26.
10. United Nations Office on Drugs and Crime [UNODC] (2005). *World Drug Report, United Nations, Geneva, Switzerland* (p.23). Accessed at:
http://www.unodc.org/pdf/WDR_2005/volume_1_chap1_dynamics.pdf
11. Thiede H, Valleroy LA, MacKellar DA, Celentano DD, Ford WL, Hagan H, Koblin BA, LaLota M, McFarland W, Shehan DA, Torian LV; Young Men's Survey Study Group. Regional patterns and correlates of substance use among young men who have sex with men in 7 US urban areas. *Am J Public Health.* 2003; *93*:1915-21.
12. Reback CJ. The social construction of a gay drug: methamphetamine use among gay and bisexual males in Los Angeles. City of Los Angeles Report. 1997. Available at:
http://www.uclaisap.org/documents/final-report_cjr_1-15-04.pdf.
13. Schilder AJ, Lampinen TM, Miller ML, Hogg RS. Crystal methamphetamine and ecstasy differ in relation to unsafe sex among young gay men. *Can J Public Health.* 2006; *96*:340-3.
14. Diaz RM, Heckert AL, Sanchez J.(2005) Reasons for stimulant use among Latino gay men in San Francisco: a comparison between methamphetamine and cocaine users. *J Urban Health.* *82*(1 Suppl 1):i71-8.
15. Brecht ML, O'Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. *Addict Behav.* 2004. *29*:89-106.

16. Worth H, Rawstorne P. Crystallizing the HIV epidemic: methamphetamine, unsafe sex, and gay diseases of the will. *Arch Sex Behav*. 2005; 34:483-6.
17. Peck JA, Reback CJ, Yang X, Rotheram-Fuller E, Shoptaw S. Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. *J Urban Health*. 2005; 82(1 Suppl 1):i100-8.
18. Purcell DW, Wolitski RJ, Hoff CC, Parsons JT, Woods WJ, Halkitis PN. Predictors of the use of viagra, testosterone, and antidepressants among HIV-seropositive gay and bisexual men. *AIDS*. 2005; 19 Suppl 1:S57-66.
19. Reback CJ, Larkins S, Shoptaw S. Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. *AIDS Behav*. 2004; 8:87-98.
20. Ibanez GE, Purcell DW, Stall R, Parsons JT, Gomez CA. Sexual risk, substance use, and psychological distress in HIV-positive gay and bisexual men who also inject drugs. *AIDS* 19 2005. Suppl 1:S49-55.
21. Semple SJ, Patterson TL, Grant I. A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men. *Drug Alcohol Depend*. 2004; 76:203-12.
22. Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. *Sex Transm Dis*. 2006; 33:250-5.
23. Buchbinder SP, Vittinghoff E, Heagerty PJ, Celum CL, Seage GR 3rd, Judson FN, McKirnan D, Mayer KH, Koblin BA. Sexual risk, nitrite inhalant use, and lack of circumcision

- associated with HIV seroconversion in men who have sex with men in the United States. *J Acquir Immune Defic Syndr.* 2005; 39:82-9.
24. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. *J Am Pharm Assoc.* 2005; 45:63-72.
25. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2004. Vol. 16. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
26. Xia Q, Osmond DH, Tholandi M, Pollack LM, Zhou W, Ruiz JD, Catania JA. HIV prevalence and sexual risk behaviors among men who have sex with men: results from a statewide population-based survey in California. *J Acquir Immune Defic Syndr.* 2006; 41:238-45.
27. Buchacz K, McFarland W, Kellogg TA, Loeb L, Holmberg SD, Dilley J, Klausner JD. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. *AIDS.* 2005; 19:1423-4.
28. Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. *Sex Transm Dis.* 2005; 32:458-63.
29. Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. *Lancet.* 2004; 364:41-50.
30. Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E; the EXPLORE Study Team. Longitudinal patterns of methamphetamine, popper (amyl

- nitrite), and cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men. *Journal of Urban Health*. 2005. 82(1 Suppl 1):i62-70.
31. Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA., Cheever L., Johnson M, Paxton LA, Onorato IM, Greenberg AE. Antiviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. *MMWR* Jan 21 2005; 54(RR02):1-20.
32. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH; Praca Onze Study Team. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. *J Acquir Immune Defic Syndr*. 2004; 35:519-25.
33. Lacombe K, Dagueneil-Nguyen A, Lebeau V, Fonquernie L, Girard PM, Meyohas MC. Determinants of adherence to non-occupational post HIV exposure prophylaxis. *AIDS*. 2006; 20:291-4.
34. Hamlyn E, McAllister J, Winston A, Sinclair B, Amin J, Carr A, Cooper DA. Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile? *Sex Transm Infect*. 2006; 82:21-3.
35. Fiore MC, Bailey WC, Cohen SJ, et al. (2000). *Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians*. Rockville, MD: US Department of Health and Human Services. US Public Health Service. Available at:
<http://www.surgeongeneral.gov/tobacco/tobaqrg.htm>.
36. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J, Methamphetamine Treatment Project Corporate Authors. A multi-site comparison of

psychosocial approaches for the treatment of methamphetamine dependence. *Addiction*. 2004; 99:708-17.

37. Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E, Larkins S, Veniegas RC, Freese TE, Hucks-Ortiz C. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. *Drug and Alcohol Dependence*. 2005; 78:125-134.